Predict your next investment

Asset/Investment Management
FINANCIAL | Investment Firms & Funds
ghif.com

See what CB Insights has to offer

Investments

15

Portfolio Exits

5

Funds

4

About Global Health Investment Fund

The Global Health Investment Fund (GHIF) is an impact investment fund designed to provide financing to advance the development of drugs, vaccines, diagnostics, and other interventions against diseases that disproportionately burden low-income countries. The Fund provides a novel opportunity to help bring about significant improvements in the treatment and prevention of disease, in family planning, and in the reduction of maternal and child mortality, along with the prospect of a net financial return for investors.

Global Health Investment Fund Headquarter Location

501 Fifth Avenue Suite 1404

New York, New York, 10017,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Global Health Investment Fund Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Global Health Investment Fund Rank

Latest Global Health Investment Fund News

The Global Health Investment Fund Exits Position in Alydia Health, Following Acquisition by Organon

Jun 21, 2021

06/21/2021 | 09:01am EDT Message : *Required fields NEW YORK, June 21, 2021 /PRNewswire/ --  The Global Health Investment Fund  (GHIF) is pleased to announce the successful exit from its investment in Alydia Health , following the completion of a previously announced acquisition of Alydia by Organon, a spinoff of Merck. GHIF, which led the Series B financing for Alydia Health in September 2018, achieved a 5x return on behalf of its investors. Alydia is the eighth company from GHIF's 12-company portfolio to generate realized returns for investors. Founded in 2010, Alydia Health is a commercial-stage medical device company focused on preventing maternal morbidity and mortality caused by postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding. Alydia Health's device, the Jada System, is designed to encourage normal contraction of the uterus to stop excessive bleeding after childbirth. The Series B funding round by GHIF supported and financed Alydia Health's pivotal PEARLE Study. The Series C funding, led by AXA Investment Managers with support from GHIF, culminated in the U.S. Food and Drug Administration (FDA) granting 510(k) clearance to the Jada System in September 2020. "We're thrilled by this major milestone that the Alydia team has achieved on its path to commercializing the Jada System globally. We're proud of Alydia's achievements and are confident that the lives of mothers and families worldwide will be improved through Organon's global reach," said Curt LaBelle, MD, Managing Partner of the Global Health Investment Fund and Board Chair for Alydia Health. "We're grateful to have received ongoing and thoughtful support from Curt and GHIF as we've taken the Jada System from the research stage to commercialization," added Rob Binney, chief executive officer, Alydia Health. "As we look to improve the safety of childbirth and improve the standards of maternal care, we believe this acquisition is the next step in our goal to broadly deliver our innovative product to those in need." About Global Health Investment Fund GHIF is a social impact investment fund structured by JPMorgan Chase & Co. and the Bill & Melinda Gates Foundation. With an emphasis on late-stage projects, GHIF finances the development of drugs, vaccines, devices, and diagnostics for diseases that disproportionately burden low-income populations. Key global health challenges targeted by the fund include malaria, tuberculosis, HIV/AIDS, cholera, and preventable causes of maternal and infant mortality, in addition to other neglected infectious diseases. GHIF's definition of success requires meaningful improvements in the lives of those afflicted by these challenges, and the fund forecasts and measures its progress against this objective alongside traditional financial return benchmarks. For additional information about GHIF, please visit ghif.com . About Alydia Health Founded in 2010 with a vision to make childbirth safer for all mothers, Alydia Health is a commercial-stage medical device company focused on preventing maternal morbidity and mortality caused by postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding – a challenging condition to manage and a growing problem in the U.S. and globally. Alydia's device, the Jada® System, is designed to encourage normal contraction of the uterus to stop excessive bleeding after childbirth. Alydia received 510(k) clearance (marketing authorization) from the FDA for the Jada® System in August 2020 based on results from the company's pivotal PEARLE IDE Study. Media contact:

Global Health Investment Fund Investments

15 Investments

Global Health Investment Fund has made 15 investments. Their latest investment was in Revelation Biosciences as part of their Series A on January 1, 2021.

CBI Logo

Global Health Investment Fund Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/6/2021

Series A

Revelation Biosciences

$9.1M

Yes

1

7/30/2020

Series C

Alydia Health

$13.9M

No

4

9/18/2019

Series D

Themis Bioscience

$44M

No

3

2/18/2019

Series A

Subscribe to see more

$99M

Subscribe to see more

10

11/7/2018

Unattributed

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/6/2021

7/30/2020

9/18/2019

2/18/2019

11/7/2018

Round

Series A

Series C

Series D

Series A

Unattributed

Company

Revelation Biosciences

Alydia Health

Themis Bioscience

Subscribe to see more

Subscribe to see more

Amount

$9.1M

$13.9M

$44M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

4

3

10

10

Global Health Investment Fund Portfolio Exits

5 Portfolio Exits

Global Health Investment Fund has 5 portfolio exits. Their latest portfolio exit was Revelation Biosciences on August 30, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/30/2021

Acq - Pending

$991

2

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

8/30/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Exit

Acq - Pending

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

Global Health Investment Fund Fund History

4 Fund Histories

Global Health Investment Fund has 4 funds, including Global Health Investment Fund I.

Closing Date

Fund

Fund Type

Status

Amount

Sources

1/2/2014

Global Health Investment Fund I

$66.77M

1

1/2/2014

Global Health Investment Fund I Offshore

Subscribe to see more

$99M

10

12/19/2013

The Global Health Investment Fund

Subscribe to see more

$99M

10

The Global Health Investment Fund II

Subscribe to see more

$99M

10

Closing Date

1/2/2014

1/2/2014

12/19/2013

Fund

Global Health Investment Fund I

Global Health Investment Fund I Offshore

The Global Health Investment Fund

The Global Health Investment Fund II

Fund Type

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Amount

$66.77M

$99M

$99M

$99M

Sources

1

10

10

10

Global Health Investment Fund Team

1 Team Member

Global Health Investment Fund has 1 team member, including current President, Curt Labelle.

Name

Work History

Title

Status

Curt Labelle

Tullis Health Investors, and Investor Growth Capital

President

Current

Name

Curt Labelle

Work History

Tullis Health Investors, and Investor Growth Capital

Title

President

Status

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.